Archive

This in vitro study tested whether a 50 Hz, 20 mT extremely low-frequency electromagnetic field (ELF-EMF) enhances the cytotoxic effects of doxorubicin (DOX) in the MCF-7 breast cancer cell line. The authors report that combining ELF-EMF with low-dose DOX reduced cell viability at lower DOX concentrations than DOX…

This single-site feasibility trial evaluated repeated 90-minute amplitude-modulated EMF exposure (AutEMdev) in 66 patients with advanced hepatocellular carcinoma. The primary focus was safety and hemodynamic variability during exposure, with exploratory outcomes including quality of life, survival, and tumor…

This in vitro study assessed 50 Hz, 100 G extremely low-frequency EMF in combination with temozolomide and radiation in T98 glioblastoma cells grown as monolayers and spheroids. Radiation plus EMF increased apoptosis-related gene expression, while temozolomide plus EMF increased autophagy marker expression compared…

This review discusses low-energy amplitude-modulated RF EMF (27.12 MHz carrier with low Hz–kHz envelope modulation) delivered systemically via intrabuccal antenna devices as a potential treatment for advanced hepatocellular carcinoma. It reports preclinical inhibition of cancer growth in vitro and in mouse xenograft…

This in vitro study exposed two human breast cancer cell lines to a 50 Hz ELF-EMF (20 mT) for 3 hours/day for up to four days. The authors report reduced viability and apoptosis-related findings in MDA-MB-231 cells, with no significant viability change in MCF-7 cells. Cell-cycle effects differed by cell line,…

This in vitro study tested an ELF-EMF at a calculated thermal resonant frequency in 2D and 3D culture models of human pancreatic cancer, glioblastoma, and breast cancer. The authors report reduced cell growth and a metabolic shift, including potentiation of coupled and uncoupled respiration and altered transcription…

This in vitro study evaluated short-term extremely low frequency electromagnetic field (ELF-EMF) exposure and silver nanoparticles (AgNPs), alone and combined, for antibacterial effects and apoptosis induction in MCF-7 breast cancer cells. The authors report time-dependent reductions in bacterial viable counts, with…

This in vitro study tested continuous or pulsed ELF electromagnetic field exposure in human cancer cells treated with the anticancer agent 3-bromopyruvate (3BP). The authors report that ELF-EMF enhanced 3BP anti-cancer activity, which they link to reduced TNFα secretion, p21/p27-associated G2/M arrest, and cancer…

This in vitro study evaluated 50 Hz, 70 G electromagnetic field exposure in combination with temozolomide (TMZ) in T98 and A172 glioblastoma cell lines. The authors report that EMF plus TMZ increased cell death and reduced migration potential compared with controls. They also report increased p53 gene expression and…

This animal study compared 50 Hz extremely low-frequency EMF exposure with doxorubicin (and their combination) in Walker-256 carcinosarcoma-bearing rats, assessing tumor growth and liver redox-related outcomes. DOX and DOX+EMF were reported to inhibit tumor growth more than EMF alone, though EMF alone also showed an…

This animal and in vitro study examined ELF magnetic field exposure in a mouse breast tumor model and a breast cancer cell line. The authors report tumor growth suppression and reduced expression of Ki-67, CD31, VEGFR2, and MMP-9 after exposure. They also report increased IFN-γ and TNF-α and increased…

This pooled case series evaluated amplitude-modulated 27.12 MHz RF EMF delivered via the TheraBionic P1 device (3 hours daily) in patients with advanced hepatocellular carcinoma, comparing outcomes to historical controls. The authors report longer median overall survival for Child-Pugh A patients versus comparable…

This article reviews Italian jurisprudence on alleged occupational tumours linked to RF EMF exposure (notably from wireless phones), with some cases also involving other RF sources or ELF magnetic fields. It contrasts court decisions that recognized occupational causation with others that rejected it, emphasizing how…

This narrative review synthesizes evidence up to September 2019 on health risks from radiofrequency exposure emitted by mobile phones, in the context of IARC's 2013 Group 2B classification. The authors report that the literature does not show a clear risk profile and cannot definitively confirm or refute a health…

This in vitro study evaluated whether extremely low-frequency EMF exposure (100 Hz, 100 G) modifies the effects of temozolomide (100 µM) in human glioblastoma U87 cells over 120–144 hours. The authors report that combined treatment reduced stemness-associated markers (Nestin, CD133, Notch4) and increased GFAP…

This study describes a therapeutic use of athermal, amplitude-modulated RF EMF (27.12 MHz) at breast cancer-specific frequencies to target breast cancer brain metastases. The abstract reports tumor growth suppression in animal models and durable regression in one patient with triple negative breast cancer brain…

This EBioMedicine commentary discusses tumour-specific amplitude-modulated RF EMF as an anti-cancer therapy for hepatocellular carcinoma and highlights Cav3.2 (CACNA1H) T-type calcium channels as a proposed mediator of the effect. It notes that the reported whole-body averaged SAR in a treated HCC patient was below…

This paper presents a theoretical model analyzing parameters that may optimize metal nanoparticle-aided EMF photothermal therapy effects on cancer cells. The model suggests efficacy depends on both electric field enhancement and thermal (hyperthermia) contributions, influenced by nanoparticle absorption properties…

This in vitro study exposed cancer (U87-MG; 143B) and noncancerous (BJ; HEK) cells to extremely low frequency electromagnetic fields under varying frequencies (2–60 Hz), waveforms, and exposure durations, with sham controls. Cell viability was assessed using an MTT assay. The authors report that cancer and…